Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Later it was shown in ab initio calculations with the high level of accuracy that the Rf atom has the ground state with the 6d2 7s2 valence configuration and the low-lying excited 6d1 7s2 7p1 state with the excitation energy of only 0.3–0.5 eV. In an analogous manner to zirconium and hafnium, rutherfordium is projected to form a very stable, refractory oxide, RfO2. It reacts with halogens to form tetrahalides, RfX4, which hydrolyze on contact with water to form oxyhalides RfOX2. The tetrahalides are volatile solids existing as monomeric tetrahedral molecules in the vapor phase. In the aqueous phase, the Rf4+ ion hydrolyzes less than titanium(IV) and to a similar extent as zirconium and hafnium, resulting in the RfO2+ ion. Treatment of the halides with halide ions promotes the formation of complex ions. The use of chloride and bromide ions produces the hexahalide complexes RfCl2−6 and RfBr2−6. For the fluoride complexes, zirconium and hafnium tend to form hepta- and octa- complexes. Thus, for the larger rutherfordium ion, the complexes RfF2−6, RfF3−7 and RfF4−8 are possible.
Israeli airstrikes hit Iranian oil storage facilities, killing four people. Strikes on fuel depots near Tehran caused a "river of fire" to pour out along the streets, and the city became engulfed in thick black smoke, causing toxic acidic rain to fall in the surrounding area. US Central Command announced the death of a seventh US service member from an Iranian attack. The UK confirmed its forces had intercepted an Iranian drone headed towards Iraq, and declared its intention to send a Merlin helicopter to the region to detect aerial threats. According to the Iranian Red Crescent Society, 65 schools and 32 medical facilities had been targeted, and more than 10,000 civilian sites damaged. On 9 March, NATO confirmed the interception of a second ballistic missile in Turkish airspace. Turkey deployed six F-16s and air defense systems to Northern Cyprus. Trump claimed that "the war is very complete, pretty much", after speaking with Russian president Putin, and said "we already won the war in many ways." Following Syrian president Ahmed al-Sharaa's support for Lebanon's objective to disarm Hezbollah, the group targeted the city of Inkhil in Syria. About a dozen B-1B bombers arrived at bases in Europe.
He announced the construction of seventeen "large schools" in different regions of the country, intended to offer high-quality education and modern equipment, seeking to reduce school dropout and improve learning indicators. Peña expressed enthusiasm for this project and acknowledged that there were still challenges to overcome in the national education system. In March 2025, the president highlighted the historic delivery of 430,000 school furniture items as part of the strengthening of the education system and the improvement of learning conditions. He announced the expansion of places for government scholarships, benefiting more students who passed the tests and met the established requirements.
Surgical and medical treatment: Complications from gallbladder surgery can lead to biliary fistulas. As well as being congenital or resulting from trauma, arteriovenous fistulas are created purposefully for hemodialysis. Radiation therapy to the pelvis can lead to vesicovaginal fistulas. Persistent gastrocutaneous fistulas can develop after gastrostomy. Trauma: Prolonged childbirth can lead to fistulas in women, in whom abnormal connections may occur between the bladder and vagina, or the rectum and vagina. An obstetric fistula develops when blood supply to the tissues of the vagina and the bladder (and/or rectum) is cut off during prolonged obstructed labor. The tissues die and a hole forms through which urine and/or feces pass uncontrollably. Vesicovaginal and rectovaginal fistulas may also be caused by rape, in particular gang rape, and rape with foreign objects, as evidenced by the abnormally high number of women in conflict areas who have developed fistulae. In 2003, thousands of women in eastern Congo presented themselves for treatment of traumatic fistulas caused by systematic, violent gang rape, often also with sharp objects that occurred during the country's five years of war. So many cases have been reported that the destruction of the vagina is considered a war injury and recorded by doctors as a crime of combat. Head trauma can lead to perilymph fistulas, whereas trauma to other parts of the body can cause arteriovenous fistulas.
trend predicted for rigid elastic spheres. Indeed, the Chapman–Enskog analysis shows that the predicted temperature dependence can be tuned by varying the parameters in various molecular models. A simple example is the Sutherland model, which describes rigid elastic spheres with weak mutual attraction. In such a case, the attractive force can be treated perturbatively, which leads to a simple expression for
Sources: en.wikipedia.org
Pesce (1983), co-creator of The Adventures of Chico and Guapo, director of From Dusk Till Dawn 3: The Hangman's Daughter Lodge Kerrigan (1985), motion picture screenwriter and director of Rebecca H. Scott McGehee (1985), director of Uncertainty Katharina Otto-Bernstein (1986), Emmy Award-nominated filmmaker, producer, screenwriter daughter of German industrialist Werner Otto, billionaire heiress to the Otto GmbH fortune Cecily Rhett (1987), film editor, Stranger Inside Garth Stein (1987), Academy Award-winning producer, The Lunch Date Dan Futterman (1989), two-time Academy Award nominee for writing Capote and Foxcatcher Jessica Bendinger (1988), writer of Bring it On and for Sex and the City Andrew W.
The Academy of Clinical Laboratory Physicians and Scientists is a learned society for scientists in the fields of clinical pathology and laboratory medicine. It was founded on November 12, 1966, in Bethesda, Maryland by a group of fifty-one individuals, led by David Seligson, Jon Straumfjord, George Z. Williams, Ernest Cotlove, and Ellis Benson. The society's founding mission was to represent scientists in the fields of clinical pathology and laboratory medicine in both the United States and Canada. As of 2015, it had 295 active members, as well as an additional 127 associate members, 195 emeritus members, and 5 honorary members. Along with the American Society for Clinical Pathology, it co-sponsors the American Journal of Clinical Pathology.
== External links == A more advanced video detailing the different types of post-translational modifications and their chemical structures A useful video visualising the process of converting DNA to protein via transcription and translation Video visualising the process of protein folding from the non-functional primary structure to a mature, folded 3D protein structure with reference to the role of mutations and protein mis-folding in disease
Dissolvable or swelling microneedles would provide those who are limited in their ability to seek hospital care with the ability to safely administer drugs in the comfort of their homes, although disposal of solid or hollow microneedles could still pose a needle-stick or blood borne pathogen infection risk. Another benefit of microneedles is their lower rates of microbial invasion into delivery sites. Traditional injection methods can leave puncture wounds for up to 48 hours post-treatment. This leaves a large window of opportunity for harmful bacteria to enter into the skin. Microneedles only damage the skin to a depth of 10-15μm, making it difficult for bacteria to enter the bloodstream and giving the body a smaller wound to repair. Further research is required to determine the types of bacteria able to breach the shallow puncture site of microneedles.
The skin of the hands and fingers and the feet and toes is known by forensic scientists as friction ridge skin. It is known by anatomists as thick skin, volar skin or hairless skin. It has raised ridges, a thicker and more complex epidermis, increased sensory abilities, and the absence of hair and sebaceous glands. The ridges increase friction for improved grasping. In mucous membranes, the equivalent structures to dermal papillae are generally termed "connective tissue papillae", which interdigitate with the rete pegs of the superficial epithelium. Dermal papillae are less pronounced in thin skin areas.
Sources: en.wikipedia.org
Plutonium-244 (244Pu) is an isotope of plutonium that has a half-life of 81.3 million years. This is longer than any other isotope of plutonium and longer than any other known isotope of an element beyond bismuth, except for the three naturally abundant ones: uranium-235 (704 million years), uranium-238 (4.463 billion years), and thorium-232 (14.0 billion years). Given the half-life of 244Pu, an exceedingly small amount should still be present on Earth, making plutonium a likely but unproven candidate as the shortest-lived primordial element.
== History == Ziprasidone is chemically similar to risperidone, of which it is a structural analogue. It was first synthesized in 1987 at the Pfizer central research campus in Groton, Connecticut. Phase I trials started in 1995. In 1998 ziprasidone was approved in Sweden. After the FDA raised concerns about long QT syndrome, more clinical trials were conducted and submitted to the FDA, which approved the drug on February 5, 2001.
In the ensuing power struggle for control over the province, General Wang Zuanxu made a deal with Liu that he would return the Ya'an and Xichang regions to Xikang as well as subsidize the Xikang government with 360,000 yuan per year in exchange for Liu's support. This deal went through, and the central government even agreed to fund a highway from Sichuan to Xikang. On 28 November, 1938, the Executive Yuan ratified the establishment of Xikang Province, which was officially inaugurated on 1 January, 1939. Liu Wenhui became the governor of Xikang. In exchange, Wang Zuanxu was able to become the acting chairman of Sichuan Province, although he failed to secure control and was later usurped by Chiang Kai-shek himself. Liu Wenhui's provincial government was highly nepotistic, made up mostly of personal connections, secretaries, and subordinate officers. Only one politician in the new government, Ye Xiufeng, was a Chiang loyalist: he was subsequently outmaneuvered by Liu and dismissed within two years. Although the Tibetan population were hopeful that the establishment of the province would entail increased representation, Liu only appointed one Tibetan, a monk, to the governing board. This was justified by the national government as a prioritization of national stability over minority rights, ensuring that the Xikang government remained Han-centric and Han-dominant. In addition, the wartime situation meant that by cooperating with the central government, Liu Wenhui would be able to maintain his rule over Xikang.
To facilitate the work of the CDC, a Medical Laboratory Services Advisory Committee was appointed. Inhorn was the only State Laboratory Director to serve on the MLSAC Advisory Committee, perhaps because the WSLH had a strong history of proficiency testing in clinical laboratories in Wisconsin. Inhorn's assignment for CLIA-67 was to develop a protocol for PT programs to be used in the future. Many changes had been made to CLIA-67, but major weaknesses in the program still existed. It would take another two decades before new federal legislation, called CLIA-88, would address these shortcomings. Inhorn was appointed to the new CLIA-88 advisory board and served during the first two years of its existence. During the ensuing years, many more health laboratories opened in the U.S. and new technology introduced built-in controls, so that performance was validated without confirmation by laboratory workers.
Clicked peptide polymers are poly-triazole-poly-peptide hybrid polymers. They are made of repeating units of a 1,2,3-triazole and an oligopeptide. They can be visualized as an oligopeptide that is flanked at both the C-terminus and N-terminus by a triazole molecule.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.